AorTech International PLC New Patent Issued (6329S)
June 26 2018 - 6:49AM
UK Regulatory
TIDMAOR
RNS Number : 6329S
AorTech International PLC
26 June 2018
26 June 2018
AorTech International plc
("AorTech" or the "Company")
New Patent Issued
AorTech is pleased to announce that the US Patent Office has
recently granted Patent Number 9,994,668 entitled "BIOSTABLE
POLYURETHANES". The invention relates to polyurethanes and
processes for their preparation. The polyurethanes are biostable,
creep resistant, acid resistant and abrasion resistant which makes
them useful in the manufacture of biomaterials and medical devices,
articles or implants, in particular, long term implantable medical
devices in the fields of cardiology, orthopaedics, plastic surgery
and gastroenterology.
Bill Brown, Chairman of AorTech said: "We are delighted that
this US Patent has been issued extending further AorTech's world
class portfolio of biostable polymers for medical device use."
For further information contact:
AorTech International plc Tel: +44 (0)7730 718296
Bill Brown, Chairman
Stockdale Securities Limited Tel: +44 20 7601 6100
Tom Griffiths/David Coaten
About AorTech:
AorTech has developed biostable, implantable polymers, including
Elast-Eon(TM) and ECSil(TM) the world's leading long-term
implantable co-polymers, now manufactured on their behalf by
Biomerics LLC in Utah, USA. With several million implants and seven
years of successful clinical use, AorTech polymers are being
developed and used in cardiology and urological applications,
including pacing leads, cardiac cannulae, stents and neuro
stimulation devices. Devices manufactured from AorTech polymers
have numerous US FDA PMA approvals, 510ks, CE Marks, Australian TGA
and Japanese Ministry of Health approvals.
Elast-Eon(TM) and ECSil(TM)'s biostability is comparable to
silicone while exhibiting excellent mechanical, blood contacting
and flex-fatigue properties. These polymers can be processed using
conventional thermoplastic extrusion and moulding techniques. A
range of materials in a variety of application-specific
formulations for use in medical devices and components are
available.
In addition to the licensing of biostable polymers, AorTech is
now developing medical devices utilising the key properties of its
world class polymers.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCLLFSLREIRFIT
(END) Dow Jones Newswires
June 26, 2018 07:49 ET (11:49 GMT)
Rua Life Sciences (LSE:RUA)
Historical Stock Chart
From Apr 2024 to May 2024
Rua Life Sciences (LSE:RUA)
Historical Stock Chart
From May 2023 to May 2024